Gynecological Follow-upSuivi-gynécoNCT07424937
Prevalence of Regular Gynecological Follow-up Among Women of Childbearing Age
An observational study of Gynecological Follow-up, run by Université de Reims Champagne-Ardenne at 1 site in France.
Trial summary
The French National Authority for Health (Haute Autorité de Santé, HAS) recommends regular gynecological follow-up, specifying that it is considered regular when it is annual. The objectives of this gynecological follow-up are multiple: to support women in the choice and management of contraception as well as in their… Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Gynecological Follow-up
- What is being tested?
- data collection
- How many people
- 395 participants
- Where
- 1 siteFrance
- Study dates
- 1 Dec 2025to 1 Feb 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult women, non-menopausal, with or without desire for pregnancy, not pregnant, and agreeing to participate in the study
Who may be able to join
- Women aged 18 years and over
- Are not menopausal
- Have or do not have a desire for pregnancy
- Have children or do not have children
- Have a sexual partner or not
- Reside in metropolitan France or in the French overseas department.
- Agreeing to participate in the study
Who cannot join
- Being pregnant
- Being legally protected (guardianship, curatorship, judicial protection)
Trial locations and contacts
1 site in 1 country.
About this study
The French National Authority for Health (Haute Autorité de Santé, HAS) recommends regular gynecological follow-up, specifying that it is considered regular when it is annual. The objectives of this gynecological follow-up are multiple: to support women in the choice and management of contraception as well as in their sexuality; to screen for cervical cancer and breast cancer; to diagnose and to take care of sexually transmitted infections (STIs); and to diagnose and treat gynecological conditions such as adenomyosis, endometriosis, polycystic ovary syndrome, etc. Regarding cervical cancer screening, the HAS recommends performing a Pap smear (cervical cytology) starting at the age of 25 and up to the age of 65.
Several studies, such as those by Henry et al. in 2020 and Owokuhaisa et al. in 2024, have identified major barriers to access to gynecological care for women. These barriers include very long waiting times, lack of privacy, lack of understanding or access to appropriate information, discomfort or fear during consultations, shortage of physicians, past negative experiences, etc. These factors may contribute to women postponing or even forgoing their gynecological consultations. A study by Landy et al. in 2021 also showed that women diagnosed with advanced-stage cervical cancer had not undergone regular screening or gynecological follow-up.
Read the detailed description
Objectives Primary: To describe the prevalence of regular gynecological follow-up among women of childbearing age.
Secondary:
- To describe women's knowledge regarding gynecological follow-up
- To investigate the factors associated with women's regular gynecological follow-up, particularly the desire for pregnancy
- Conditions
- Gynecological Follow-up
- Being tested
- data collection
- Keywords
- gynecological follow-up, regular, childbearing age, woman
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
data collectionOther
data collection
What is being measured
The primary outcome is the main question the study is designed to answer.
The prevalence of regular gynecological follow-up
Regular gynecological follow-up (according to HAS recommendations: once per year) and, if irregular, the frequency of follow-up: once every two to three years, occasionally, more than three years ago, or never consulted
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2026
- Study start1 Dec 2025
- Primary completion30 Jan 2026
- Study completion1 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gynecological Follow-upStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 395 participants (actual)
Sponsor and investigators
- Lead sponsor
- Université de Reims Champagne-Ardenne
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07424937
- Sponsor's protocol ID
- 2025_RIPH_17_SF_A Fillion
- Acronym
- Suivi-gynéco
- Status last verified
- Feb 2026
- First submitted
- 13 Feb 2026
- Last updated
- 20 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Regular Gynecological Follow-up Among Women of Childbearing Age
- ClinicalTrials.gov ID
- NCT07424937
- Acronym / sponsor ID
- Suivi-gynéco / 2025_RIPH_17_SF_A Fillion
- Conditions
- Gynecological Follow-up
- Keywords
- gynecological follow-up, regular, childbearing age, woman
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 395 participants (actual)
- Lead sponsor
- Université de Reims Champagne-ArdenneUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 30 Jan 2026 (actual)
- Study completion
- 1 Feb 2026 (actual)
- First posted
- 20 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The French National Authority for Health (Haute Autorité de Santé, HAS) recommends regular gynecological follow-up, specifying that it is considered regular when it is annual. The objectives of this gynecological follow-up are multiple: to support women in the choice and management of contraception as well as in their sexuality; to screen for cervical cancer and breast cancer; to diagnose and to take care of sexually transmitted infections (STIs); and to diagnose and treat gynecological conditions such as adenomyosis, endometriosis, polycystic ovary syndrome, etc. Regarding cervical cancer screening, the HAS recommends performing a Pap smear (cervical cytology) starting at the age of 25 and up to the age of 65.
Several studies, such as those by Henry et al. in 2020 and Owokuhaisa et al. in 2024, have identified major barriers to access to gynecological care for women. These barriers include very long waiting times, lack of privacy, lack of understanding or access to appropriate information, discomfort or fear during consultations, shortage of physicians, past negative experiences, etc. These factors may contribute to women postponing or even forgoing their gynecological consultations. A study by Landy et al. in 2021 also showed that women diagnosed with advanced-stage cervical cancer had not undergone regular screening or gynecological follow-up.
Detailed description
Objectives Primary: To describe the prevalence of regular gynecological follow-up among women of childbearing age.
Secondary:
- To describe women's knowledge regarding gynecological follow-up
- To investigate the factors associated with women's regular gynecological follow-up, particularly the desire for pregnancy
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult women, non-menopausal, with or without desire for pregnancy, not pregnant, and agreeing to participate in the study
Key inclusion criteria (7 listed)
- Women aged 18 years and over
- Are not menopausal
- Have or do not have a desire for pregnancy
- Have children or do not have children
- Have a sexual partner or not
Key exclusion criteria (2 listed)
- Being pregnant
- Being legally protected (guardianship, curatorship, judicial protection)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| data collectiondata collection | Other | – |
Primary outcome
The prevalence of regular gynecological follow-up
Time frame: Day 0
Regular gynecological follow-up (according to HAS recommendations: once per year) and, if irregular, the frequency of follow-up: once every two to three years, occasionally, more than three years ago, or never consulted
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Gynecological Follow-up
Recruiting
Randomized Study of a Dematerialized Management for Post-Emergency Gynecological Follow-Up
Genital Diseases, Female, Ectopic Pregnancy
Active, not recruitingObservational study
Follow-up in Gynecological Cancer Survivors
Gynecologic Cancer
RecruitingObservational study
Evaluation of the Quality of Life and Gynecological Follow-up of Patients Treated for Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome
Mrkh Syndrome
RecruitingObservational study
Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
Human Papilloma Virus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gynecological Follow-up, run by Université de Reims Champagne-Ardenne at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The prevalence of regular gynecological follow-up (time frame: Day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2026.